Worried about the HPV vaccine causing horrific side effects, not being effective, not necessary, and scary? You should be. Post market surveillance and a new University of Maryland study highlight significant safety concerns surrounding HPV vaccines, particularly Gardasil, including increased risks of autonomic dysfunction (e.g., POTS) and menstrual irregularities, with younger recipients showing statistically significant adverse effects.
Despite Merck’s acknowledgment of deaths in clinical trials—some potentially vaccine-related—and warnings against use in pregnant women, Gardasil remains widely recommended, even as lawsuits allege withheld safety data and regulators face criticism for inadequate oversight.
As states consider mandating the vaccine, researchers and advocates urge transparent risk-benefit discussions, challenging the prevailing "announcement approach" that often omits such conversations. The findings underscore the need for further independent scrutiny and informed decision-making amid ongoing legal and scientific debates.
Study Links HPV Vaccine to Increased Risk of Autonomic Dysfunction and Menstrual Irregularities in Young Women
A new study from the University of Maryland has found that adolescent girls and young women who receive the dangerous HPV vaccine face heightened risks of autonomic dysfunction—such as postural orthostatic tachycardia syndrome (POTS)—and menstrual irregularities.
Published Tuesday in Drugs – Real World Outcomes, the peer-reviewed research analyzed insurance claims from over 78,000 young women, revealing a 23% increased risk of autonomic dysfunction and a 30% higher likelihood of menstrual irregularities post-vaccination. The findings come amid growing scrutiny of Gardasil, Merck’s HPV vaccine, and ongoing lawsuits alleging the company downplayed safety risks.
Using a self-controlled case series method, researchers compared health outcomes in young women before and after HPV vaccination. Lead authors Dr. Linda Wastila and Dr. Yu-Hua Fu found statistically significant safety signals, particularly among younger recipients. “These risks are not insubstantial,” the authors wrote, urging healthcare providers to discuss potential risks with patients—a stance that conflicts with the “announcement approach” widely promoted by public health agencies, where providers skip risk-benefit discussions.
Dr. Sin Hang Lee, a pathologist and HPV vaccine researcher, called the study “significant” as the first U.S. research to link the vaccine to these conditions. Karl Jablonowski, Ph.D., of Children’s Health Defense, added that the findings validate reports from vaccine-injured individuals long dismissed by medical authorities.
The study adds to mounting research questioning Gardasil’s long-term effects. While public health agencies emphasize its efficacy in preventing HPV-related cancers, emerging data—including Merck’s own clinical trials—have flagged safety signals like POTS and ovarian dysfunction. A 2015 BMJ investigation accused regulators of mishandling safety reviews, and lawsuits allege Merck concealed risks, including undisclosed adjuvants.
Dr. Peter C. Gotzsche, a Danish researcher, concluded in an expert report that Merck’s data manipulation made independent safety assessments “difficult if not impossible.” Despite this, Gardasil remains recommended for children as young as 9.
As states push for broader HPV vaccine mandates, the University of Maryland study underscores the need for transparent risk communication. With lawsuits pending and researchers calling for further investigation, families are urged to weigh evidence from both mainstream and independent sources before deciding. “Patients should consult their providers to discuss risks and benefits,” the authors advised—a message that challenges the status quo of vaccine policy.
Bookmark Vaccines.news to your favorite independent websites for updates on vaccines that depopulate the planet, cause infertility, and lead to Long-Vax-Syndrome.
Sources for this article include:
Please contact us for more information.